The Beauty Health Company (SKIN) Q3 2025 earnings summary

Executive summary

• Q3 2025 net sales were $70.7 million, down 10.3% year-over-year, with delivery systems down 24.6% and consumables down 2.6%, but results exceeded guidance due to operational efficiency and resilient consumables.

• Adjusted EBITDA rose to $8.9 million, up from $8.1 million in Q3 2024, reflecting cost controls and improved operational discipline.

• Net loss narrowed to $11.0 million from $18.3 million year-over-year, driven by higher gross margin and lower operational spend.

• Leadership transition completed, with new CEO focusing on device base growth, consumable utilization, innovation, and operational discipline.

• 875 delivery systems were placed in Q3 2025, down from 1,118 in Q3 2024, amid a challenging macroeconomic environment.

Financial highlights

• Gross margin improved to 64.6% from 51.6% year-over-year, mainly due to lower inventory charges and a favorable sales mix.

• Adjusted gross margin was 68.0%, slightly below 69.5% in Q3 2024, impacted by lower average selling prices.

• Adjusted EBITDA margin for Q3 was 12.6%, up from 10.2% in Q3 2024.

• Operating loss improved to $6.2 million from $21.5 million in Q3 2024.

• Cash and equivalents stood at $219.4 million as of September 30, 2025, down from $370.1 million at year-end 2024, mainly due to convertible note repurchases.

Outlook and guidance

• Full-year 2025 net sales guidance raised to $293–$300 million, with adjusted EBITDA expected at $37–$39 million.

• Q4 2025 net sales projected between $74.5 million and $81.5 million, with adjusted EBITDA between $6.9 million and $8.9 million.

• Guidance assumes no further material market deterioration and excludes unannounced M&A or financings.

• Management believes liquidity is sufficient for at least the next 12 months, with ongoing evaluation of capital needs.

• Expect continued cost management and reduced year-over-year revenue declines.